StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
Acadia Pharma (ACAD) Fades Early Gains
March 30, 2016 11:56 AM
Acadia Pharma (NASDAQ: ACAD) is fading early ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Momentum Movers
Trader Talk
Next Articles
Aegis Capital Affirms Acadia Pharma (ACAD) at 'Buy' Following Positive FDA Panel Review; Sees Nuplazid Approval Soon
March 30, 2016 10:44 AM
Needham & Company Remains Bullish on Acadia Pharma (ACAD) Following Positive FDA Vote on Nuplazid
March 30, 2016 6:49 AM
Acadia Pharmaceuticals (ACAD) PT LIfted to $44 at Piper Jaffray Amid Panel Backing for NUPLAZID
March 30, 2016 6:26 AM
Acadia Pharma (ACAD) Announces Favorable FDA Panel Vote on NUPLAZID for the Treatment of Psychosis Associated with Parkinson's Disease
March 29, 2016 5:14 PM
FDA Advisory Committee Votes 12 to 2 That Benefits of ACADIA Pharmaceuticals’ NUPLAZID™ (Pimavanserin) for the Treatment of Psychosis Associated with Parkinson’s Disease Outweigh the Risks
March 29, 2016 5:13 PM
Acadia Pharma (ACAD) wins FDA panel backing for Nuplazid - Bloomberg
March 29, 2016 3:37 PM